Product Specification
| Host |
Mouse |
| Antigen |
CD16 |
| Synonyms |
Low affinity immunoglobulin gamma Fc region receptor III-A; IgG Fc receptor III-A; CD16-II; CD16a antigen; Fc-gamma RIII-alpha (Fc-gamma RIII; Fc-gamma RIIIa; FcRIII; FcRIIIa; FcgammaRIIIA); FcR-10; IgG Fc receptor III-2; FCGR3A |
| Location |
Cell membrane |
| Accession |
P08637 |
| Clone Number |
S-R440 |
| Antibody Type |
Mouse mAb |
| Isotype |
IgG1,k |
| Application |
FCM |
| Reactivity |
Hu |
| Positive Sample |
human PBMC |
| Purification |
Protein G |
| Concentration |
0.2mg/ml |
| Conjugation |
Alexa Fluor® 488 |
| Physical Appearance |
Liquid |
| Storage Buffer |
PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage |
12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
| application |
dilution |
species |
| FCM |
5 μl per million cells in 100μl volume |
Hu |
Background
CD16, also known as FcγRIII, is a cluster of differentiation molecule found on the surface of natural killer cells, neutrophils, monocytes, macrophages, and certain T cells. CD16 has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b), which participate in signal transduction. These receptors bind to the Fc portion of IgG antibodies, which then activates antibody-dependent cell-mediated cytotoxicity (ADCC) in human NK cells. CD16 is required for ADCC processes carried out by human monocytes. In humans, monocytes expressing CD16 have a variety of ADCC capabilities in the presence of specific antibodies, and can kill primary leukemic cells, cancer cell lines, and cells infected with hepatitis B virus. In addition, CD16 is able to mediate the direct killing of some virally infected and cancer cells without antibodies.
